Assessment of CD-105 as an Angiogenic Modulator in Odontogenic Myxomas and Dental Follicles by Carmen Gonzalez-Galvan, Maria del et al.
International Journal of Surgical Pathology
2016, Vol. 24(4) 315 –319
© The Author(s) 2016
Reprints and permissions: 
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1066896916632588
ijs.sagepub.com
Original Article
Introduction
Odontogenic myxoma (OM) is a benign intraosseous neo-
plasm of the jaws with a locally aggressive behavior and a 
high recurrence rate.1-3 Its frequency ranges from 2.2% to 
17.7% of all odontogenic tumors.4-7 This tumor develops 
within a wide age range, with a greater incidence during the 
second and third decades, and has a 2 to 1 predilection for 
females. Two-thirds of the cases are located in the mandi-
ble, developing as a slow, progressive and generally asymp-
tomatic tumoral growth.1-3,5 It has a marked potential to 
infiltrate and destroy bone, and a high recurrence rate.8-10
Among the possible mechanisms of growth of OM, the 
increase in cellular proliferation,11-13 the decrease in apop-
tosis,11-13 the production of extracellular matrix degrading 
enzymes,11,14,15 the accumulation of orosomucoid-1 in the 
extracellular matrix,16,17 the induction to bone reabsorp-
tion,18 and the increase in angiogenesis and production of 
the vascular endothelial growth factor-A (VEGF-A)17 have 
been considered.
CD-105 is a homodimeric cell membrane glycoprotein, 
component of the growth factor β1 (TGF-β1) receptor-
complex that modulates angiogenesis by regulating the 
proliferation, differentiation and endothelial cell migra-
tion.19-21 The expression of CD-105 is a characteristic 
property of the newly formed blood vessels as there is a 
lack of its expression in previously-existing blood and 
lymphatic vessels.19,20,22
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Abstract
Aim. Odontogenic myxoma is a benign intraosseous neoplasm of the jaws, with a locally aggressive behavior and a high 
recurrence rate. CD-105 is a homodimeric cell membrane glycoprotein and is a component of the TGF-β1 growth factor 
receptor complex that modulates angiogenesis by regulating the proliferation, differentiation and cellular migration. 
The aim of this study is to quantify the microvascular density of the odontogenic myxoma based on the expression of 
CD-105. Materials and Methods. The analysis included 18 odontogenic myxoma and 18 dental follicles as controls. A 
standard immunohistochemical procedure was performed with the CD-105 antibody. Five representative fields (40×) 
of the odontogenic myxoma and the dental follicles were selected to determine the microvascular density, which was 
then followed by a descriptive and comparative statistical analysis. Results. Dental follicles presented a significantly higher 
microvascular density compared with odontogenic myxoma (P = .001). The odontogenic myxoma smaller than 3 cm 
showed a greater microvascular density than those larger than 3 cm in size (P > .05), and the microvascular density was 
lower in large odontogenic myxomas as compared with the dental follicles (P = .003). Conclusion. A weaker expression 
of CD-105 in odontogenic myxoma might indicate a lower angiogenic activity, suggesting that vascular proliferation has 
a limited role in the growth mechanisms and in the aggressive behavior of this neoplasm.
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The quantification of the expression of this protein has 
been proposed to evaluate neoangiogenesis in different 
types of tumors.21,23 On the other hand, microvascular den-
sity (MVD) is a useful histomorphological parameter to 
evaluate tumor angiogenesis, which is considered an indi-
cator of tumor growth, and has been correlated with the 
aggressive behavior of tumors.17,20,22
The aim of this study was to compare the MVD in OM 
and dental follicle (DF) based on the expression of CD-105, 
in an effort to obtain new information that may contribute 
to understand the possible pathogenic mechanisms impli-
cated in the growth of this neoplasm.
Materials and Methods
Tissue samples from inflammation-free areas of 18 OM 
(10 female and 8 male; with a mean age of 32.83 years; 
range 10-53 years) and of 18 DF free of inflammation (9 
female and 9 male; with a mean age of 14.4 years; range 
9-22 years) diagnosed in the Oral Pathology Laboratory 
of the Universidad Autónoma Metropolitana Xochimilco 
and in a private service of oral pathology diagnosis in 
Mexico City.
This study was approved by the Research Committee of 
the Biological and Health Sciences Division of the 
Universidad Autonóma Metropolitana Xochimilco.
Relevant information on the size of the OMs included 
in this study was obtained from the clinical files. The his-
topathological diagnosis of each case was confirmed on 
hematoxylin and eosin–stained sections and was based on 
the microscopic criteria included in the current World 
Health Organization histological classification of tumors.24 
The OMs were classified according to their size at diagno-
sis as small odontogenic myxomas (SOM), when tumors 
were up to 3 cm (n = 4), and as large odontogenic myxo-
mas (LOM) when they were larger than 3 cm (n = 14).
Two micrometer–thick sections from each paraffin 
block were deparaffinized, rehydrated and treated with 0.1 
mol/L sodium citrate (pH 6.2) to expose the antigenic epit-
opes. The endogenous peroxidases were blocked with 0.9% 
hydrogen peroxide. The primary antibody was incubated in 
a humidifying chamber (Sequenza Slide Rack) with a 1:50 
dilution of the anti-CD-105 polyclonal antibody (BioSB, 
Santa Barbara, CA, USA) and with the S2022 diluent 
(DAKO, Carpinteria, CA, USA) for 45 minutes. The reac-
tion was visualized with the Mouse/Rabbit Immunodetector 
System (BioSB, Santa Barbara, CA, USA) and revealed 
with the 3,3-diaminobenzidine hydrochloride (DAB) sub-
strate showing as a brown-colored precipitate. The samples 
were counterstained with Gill’s hematoxylin and mounted 
with a permanent medium (Eukitt).
Three oral pathologists assessed the immunohisto-
chemical expression individually before reaching a con-
sensus. The assessment criteria were based on previous 
studies.18-20,23,25,26 The standardization of the examiners 
showed a kappa index of 0.88.
The MVD was analyzed using the method proposed by 
Vered et al27 and with the grid suggested by Bologna-Molina 
et al.28 Five microphotographs of the most representative 
areas at 40× were taken with a digital camera (Olympus CX 
31; Olympus, San Diego, CA, USA). Subsequently, a 6 × 6 
grid was placed over the photograph to quantify the vessels 
located in the intersection areas (Figure 1). In cases where 
the wall or the lumen of the vessel intercepted more than 
one point, only one was taken into consideration. In each 
picture, cell counting started in the top left frame of the grid 
and finished in the top right frame (Figure 1). The number of 
positive vessels was counted manually in each image. The 
average of counts in these fields was considered in the anal-
ysis. This procedure was followed to obtain the MVD from 
the OMs and the DFs.
With all the data obtained, a descriptive and compara-
tive analysis was performed using the SPSS version 15.0 
software (SPSS Inc, IBM, Armonk, NY). The means of the 
MVD were compared with the Mann-Whitney U statistical 
Figure 1. Method employed for the microvascular density 
(MVD) analysis. Note the arrow pointing to the intersection 
coinciding with the wall of a blood vessel (40×).
Table 1. Microvascular Density (MVD) of the OMs and DFs.
Type of 
Lesion
Case 
No.
MVD
Minimum Maximum Mean (±SD) MVD
OM 18 0 1 0.29 (±0.32)
 SOM  4 0 0.8 0.4 (±0.33)
 LOM 14 0 1 0.28 (±0.32)
DF 18 0 3.4 1.27 (±1.06)
Abbreviations: OM, odontogenic myxoma; SOM, small odontogenic 
myxoma; LOM, large odontogenic myxoma; DF, dental follicle; MVD, 
microvascular density.
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test and the Kruskal-Wallis test. Significance was consid-
ered when P < .05.
Results
Table 1 shows the relevant data of the MVD found in the 
OM and DF studied cases. There was a significantly higher 
MVD in DFs as compared with OMs (P = .001). The 
expression of CD-105 in OMs and DFs is presented in 
Figure 2, showing the lack of expression of the marker in 
mature vessels.
Although SOM showed a greater MVD (0.4) than LOM 
(0.28), this difference was nonsignificant (P = .521). On 
the other hand, the MVD was lower in LOM as compared 
with the DFs (P = .003).
Discussion
Tumor growth requires blood supply to provide oxygen, 
metabolites and growth factors needed for cell prolifer-
ation. Angiogenesis is the process of formation and 
development of new blood vessels from previously exist-
ing vessels; in pathological conditions, this process 
contributes to tumor growth and favors the development 
of metastasis.
Various studies18,20,25,26 have employed the expression 
of CD-105 to assess tumor angiogenesis and the MVD in 
odontogenic tumors, and have demonstrated a greater 
specificity of CD-105 with respect to other endothelial 
markers for identification of neoangiogenesis. To our 
knowledge, this is the first study evaluating tumor angio-
genesis in OMs with CD-105.
The increase in MVD is considered an indicator of 
tumor growth and a positive predictor of metastasis, and is 
consequently associated with survival and aggressiveness 
of some neoplasms.20,22 Furthermore, it may be used to 
study the antineoplastic effect of potential angiogenic ther-
apy, even in cases of recurrent or highly aggressive odon-
togenic tumors.25
We consider that the currently available methodology 
used to quantify angiogenesis through MVD should be 
standardized with an appropriate and reproducible method 
in order to be useful for comparing data among different 
studies.18,25,26 Our work followed the method described by 
Vered et al,27 as it is the most simple and user-friendly. We 
complemented it with the grid described by our group,28 
Figure 2. Expression of CD-105 (arrows) in dental follicle (DF) (a 10×, c 40×) and in odontogenic myxoma (OM) (b 10×, d 40×). 
Note the lack of expression of the marker in mature vessels (arrowheads).
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which, to our understanding, complies with the necessary 
criteria for objectivity and reproducibility.
We observed in our study that although the OMs and 
the DFs pose similar histomorphological features, the 
tumors presented a significantly lower MVD. These results 
would support previous observations from our group17 on 
the minor role played by angiogenesis in the growth and 
aggressiveness of this neoplasm, as opposed to what seems 
to occur with the expression of CD-105 in other odonto-
genic lesions.18,26 In this regard, when comparing the 
MVD between SOM and LOM, a lower yet nonsignificant 
MVD was observed in the larger neoplasms, which could 
be associated with different stages of tumoral growth.
Cell proliferation seem to be low in OM,11-13 and thus 
it has been suggested that the growth of this tumor is 
based on its water-binding capacity that helps increase 
the hydrostatic pressure and induce the generation of 
mechanisms of bone reabsorption.11,13,29 Furthermore, a 
very recent study from our group17 demonstrated that the 
orosomucoid-1 protein is present in OM and this fact 
suggest its overexpression might be a contributing factor 
for the classical viscous and mucoid structural configura-
tion of OM, which, at least partially, is responsible for its 
invasive nature into the trabecular bone. Furthermore, a 
correlation between the expression of orosomucoid-1 and 
VEGF is described, suggesting the participation of both 
proteins in the mechanism of angiogenesis in this benign 
neoplasm.17
In conclusion, our results suggest that neoangiogenesis 
plays a minor role in the growth of the OMs and supports 
the existence of other mechanisms of expansion and pro-
gression of this neoplasm.
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